Section 8: Market Research

The following principles apply to all market research conducted by, or on behalf of, a Company.

  1. Market research must be an initiative to collect relevant information to enhance the quality use of medicines and must not be used as a means to promote to and/or reward participants.
  2. Market research may be undertaken about an approved or unapproved product or unapproved indication. For market research conducted with members of the general public, the product name and/or molecule should not be disclosed. Market research undertaken with patients who have been prescribed a particular prescription medicine may include product-specific questions.
  3. Market research studies must be clearly identified as such when the initial approach is made to participants. It must be clear to a participant that the market research is being conducted by or on behalf of a pharmaceutical Company, but the name of the pharmaceutical Company need not be disclosed. It is recognised that the disclosure of the name of the Company may bias the research.
  4. Market research should not be implemented as competitions or quizzes or in any other manner that could lead to confusion as to the purpose of the market research.
  5. Any transfer of value to a market research participant should be reasonable for the related services and consistent with upholding the integrity and reputation of the industry. Where a Company is aware of the specific named individual healthcare professionals participating in market research, payments must be disclosed in transparency reports in accordance with this Code.
Back to top